Antisense Therapeutics grants exclusive option to license anticancer compound ATL-1101 to Afandin July 5, 2011
Novartis halts phase III study of Afinitor in advanced breast cancer after meeting primary endpoint July 5, 2011
Cellceutix applies for approval to begin clinical studies with anticancer compound Kevetrin July 4, 2011
FDA committee recommends withdrawing approval for Avastin + paclitaxel in metastatic breast cancer July 4, 2011
RSS